Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 42 Parkinson Disease 4, Autosomal Dominant Lewy Body 29 Carcinoma, Renal Cell 26 Endometrial Neoplasms 13 Melanoma 10 Neoplasms 8 Uterine Cervical Neoplasms 7 Cholangiocarcinoma 7 Biliary Tract Neoplasms 7 Liver Neoplasms 6 Thyroid Neoplasms 5 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Neuroendocrine Tumors 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Esophageal Squamous Cell Carcinoma 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Thyroid Carcinoma, Anaplastic 3 Recurrence 3 Kidney Neoplasms 3 Esophageal Neoplasms 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Carcinoma, Adenoid Cystic 3 Breast Neoplasms 3 Brain Neoplasms 3 Adenocarcinoma 3 Vulvar Neoplasms 2

Interventions

pembrolizumab 5 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 cabozantinib 3 Nivolumab 3 cemiplimab 2 Ipilimumab 2 sodium thiosulfate 1 relacorilant 1 lenvatinib 1 fludarabine phosphate 1 dostarlimab 1 Radiation 1 Mitotane 1 Interleukin-13 1 Fluorodeoxyglucose F18 1 Floxuridine 1 E-7386 1 Drug Therapy 1 Dexamethasone 1 Cytoreduction Surgical Procedures 1 Cyclophosphamide 1 Cisplatin 1 CTLA-4 Antigen 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adrenocortical Carcinoma × lenvatinib × 1 year × Clear all

NCT05036434 2026-01-23

ACCOMPLISH

National Cancer Center, Korea

Phase 2 Active not recruiting

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡